A Phase 1, Randomized, Double Blind, Placebo-controlled Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-05251749 In Healthy Adult Subjects

Trial Profile

A Phase 1, Randomized, Double Blind, Placebo-controlled Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-05251749 In Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Nov 2015

At a glance

  • Drugs PF 5251749 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Oct 2015 Planned number of patients changed from 30 to 32, according to ClinicalTrials.gov record.
    • 03 Sep 2015 Planned End Date changed from 1 Sep 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top